Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial

By sjmartinez • April 1, 2025

Singh S, Nguyen JD, Fudman DI, Gerich ME, Shah SA, Hudesman D, McConnell RA, Lukin DJ, Flynn AD, Hwang C, Sprung B, Gaidos JKJ, Mattar MC, Rubin DT, Hashash JG, Metwally M, Ali T, Ma C, Hoentjen F, Narula N, Bessissow T, Rosenfeld G, McCurdy JD, Ananthakrishnan AN, Cross RK, Rodriguez Gaytan JR, Gurrola ES, Patel S, Siegel CA, Melmed GY, Weaver SA, Power S, Zou G, Jairath V, Hou JK. Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterol. 2025 Mar 31;12(1):e001615. doi: 10.1136/bmjgast-2024-001615. PMID: 40164445.

Tags: Cedars Sinai DoM, Crohn’s disease, Digestive Diseases, immunotherapy, inflammatory bowel disease, Publications

Related Posts

Let distortion-guided restoration: a physics-informed learning framework to correct prostate diffusion MRI artifacts

Long Z, Binesh N, Wang L, Malaji AV, Yang CC, Sun H, Saouaf R, Daskivich T, Kim H, Xie Y, Li D, Yang HJ. Let[...]

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial

McDonald CM, Villa C, Soslow JH, Maharry K, Hogan N, Binks M, Berth KC, Elliott KA, Taylor M, Hor KN, Signorovich J, Henricson EK, Phan[...]

Hidden risk in normal myocardial perfusion scans: AI-detected proximal coronary calcium on CT attenuation maps improves prognosis

Zhou J, Miller RJH, Shanbhag A, Killekar A, Han D, Patel KK, Pieszko K, Yi J, Urs MK, Ramirez G, Lemley M, Kavanagh PB, Liang[...]